Autism Screening with Advanced Technology: Insights from the START App

By Melike Belenli Gümüş

August 27, 2024

Introduction

Autism, a prevalent neurodevelopmental condition affecting approximately 1% globally, poses challenges in timely diagnosis, particularly in countries like India with around 5 million affected families. Limited awareness and scarce specialist resources hinder early interventions, emphasising the critical need for accessible screening tools. Addressing this, autism screening with advanced technology has seen significant advancements in recent years. An online platform, the START app is a prime example of this progress. It allows non-specialists to assess autism risk in low-resource settings, aiming to bridge the detection gap efficiently. Dubey et al. studied the app’s feasibility, accuracy, and community involvement. By understanding these aspects, we can appreciate the potential of technology in early autism detection and highlight its value in healthcare.

Feasibility and Acceptability

Researchers evaluated the START app’s feasibility through interviews with non-specialist health workers and caregivers in Delhi, India. The app was tested in home settings, ensuring real-world applicability. Non-specialist health workers conducted the interviews in Hindi.  This comprehensive approach ensured that the app could function effectively in diverse settings.

Caregivers appreciated the ease of use and the detailed feedback provided. Non-specialist health workers found the training manageable and the app user-friendly. This positive feedback indicated the app’s acceptability and potential for widespread adoption.

The app’s feasibility and acceptability translate into potential cost savings for healthcare systems. By enabling early detection and intervention, the app can reduce the long-term costs associated with untreated autism. This proactive approach aligns with value-based healthcare principles, aiming to improve patient outcomes while managing costs.

Accuracy in Classification

Researchers rigorously tested the START app’s accuracy in classifying participants, as shown in Figure 1, using machine learning methods like XGBoost, logistic regression, and support vector machines, ensuring robust results. The app effectively distinguished between typically developing children, those with autism spectrum conditions, and those with intellectual disabilities. This accuracy is vital for not only early intervention and tailored support, but also for efficient resource allocation. By identifying children needing specific interventions, healthcare providers can allocate resources more effectively, improving health outcomes and optimising healthcare funds.

Figure 1: Mean classification accuracies of the feature vectors taken from the eight START tasks. The figure also represents the most accurate classification achieved by a combination of these features.

Community Involvement

Community involvement was a cornerstone of the START app’s development. An autistic researcher participated in regular discussions during the analysis of pilot data. This inclusion ensured that the app was designed with the needs of the autism community in mind.

A dedicated dissemination event was organised for autism community stakeholders in India. Local clinicians, researchers, policymakers, and government organisation members attended. The lead researchers demonstrated the task battery and presented preliminary results in accessible language. This engagement fostered a sense of ownership and trust within the community.

Assessment Procedure

For the assessment of the START app, two high-school graduates were trained as non-specialist health workers through a four-day program, including classroom sessions and supervised field training. Psychology postgraduate research assistants oversaw the data collection, ensuring adherence to research procedures and supporting the health workers, thus maintaining data integrity.

The assessment tools included the Developmental Profile 3 (DP-3) and the INCLEN Diagnostic Tool for Autism Spectrum Disorder (INDT-ASD), administered by the research assistants for accuracy and reliability. This structured procedure ensures high-quality data, essential for evaluating the app’s effectiveness and cost-effectiveness, supporting evidence-based decision-making in value-based healthcare.

Conclusion

The START app represents a significant advancement in autism screening technology. Its feasibility and acceptability in diverse settings, combined with its accuracy in classification, make it a valuable tool. Community involvement in its development and assessment ensures it meets the needs of those it aims to serve. The app aligns with value-based healthcare principles by improving outcomes and managing costs. Furthermore, accurate classification and early intervention can lead to significant cost savings and better resource allocation. As technology continues to evolve, tools like the START app will play a crucial role in early autism detection and intervention.

Reference url

Recent Posts

drug price comparison
 

Global Drug Price Gaps Demand Better Drug Pricing Analysis

💊 International drug price comparison reveal stark price gaps—the U.S. pays 4.2 times more for brand-name drugs than OECD peers.

But are these studies fueling a market collapse or opening a strategic opportunity for sustainable pricing in the U.S. and globally?

Discover the shortcomings of international pricing comparisons and how robust drug pricing analysis can help balance access, affordability, and profitability in a complex market.

#SyenzaNews #healthcare #pricing

NICE HealthTech Reforms
            

NICE HealthTech Reforms: Accelerating Digital Innovation in NHS and Global Healthcare Systems

🌐 Are you ready to witness a paradigm shift in digital health technology?

The National Institute for Health and Care Excellence (NICE) has announced transformative reforms aimed at accelerating the adoption of digital health innovations within the NHS. By focusing on cost-effectiveness rather than mere cost savings, these changes promise to streamline regulatory processes and enhance evaluations aligned with healthcare priorities.

Dive into this insightful article to explore how NICE’s reforms could reshape the future of healthcare systems globally!

#SyenzaNews #DigitalHealth #HealthEconomics #Innovation

BioNTech BMS collaboration
   

BioNTech BMS Collaboration: Pioneering Advances in Solid Tumor Treatment with BNT327

🚀 What could a groundbreaking partnership between BioNTech and Bristol-Myers Squibb mean for the future of solid tumor therapy?

Their collaboration on BNT327 is set to revolutionize immuno-oncology with promising early-phase trial results and a strategic investment of over $1.5 billion. This innovative bispecific antibody targets both PD-L1 and VEGF-A, indicating potential for enhanced patient outcomes in challenging cancers like small cell lung cancer and triple-negative breast cancer.

Curious about how this partnership could reshape cancer treatments? Dive into the full analysis!

#SyenzaNews #oncology #drugdevelopment #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.